Otsuka picks up PTSD drug with $700M Transcend buy
BioPharma Dive
The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly paradigm-shifting therapy in psychiatry.
pharminent
March 27, 2026 (Last updated: March 30, 2026)
BioPharma Dive
The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly paradigm-shifting therapy in psychiatry.
